NDAINJECTIONINJECTABLEPriority Review
Approved
Dec 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
TRIOSTAT (liothyronine sodium) by Pfizer is synthesis. First approved in 1991.
Drug data last refreshed 35m ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIOSTAT is a synthetic liothyronine sodium (T3) injectable replacement therapy used to treat thyroid hormone deficiency and related endocrine conditions. The drug works by diffusing into cell nuclei to bind thyroid receptors and activate gene transcription, mimicking the body's natural T3 hormone which drives metabolism and physiological function. Liothyronine is the active form of thyroid hormone with more rapid onset than levothyroxine (T4).
LOE Approaching
As an aging product nearing loss of exclusivity with no patent portfolio, TRIOSTAT faces declining commercial attention and likely reduced team size and marketing investment.
Mechanism of Action
synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of thyroid…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Fasting Study of Liothyronine Sodium Tablets (50 Mcg) to Cytomel® Tablets (50 Mcg)
Started Oct 2007
31 enrolled
Healthy
Career Relevance
TRIOSTAT represents a mature, declining-revenue product with zero currently linked job opportunities, signaling limited career momentum and team contraction at sponsor Pfizer. Roles on this brand are typically focused on margin protection, cost reduction, and managed transition to generic competition rather than growth, innovation, or market expansion.
Brand Manager
Worked on TRIOSTAT at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.